Medicare GLP-1 Bridge Program: Your $50 Copay Guide (July 2026)

For years, Medicare beneficiaries who wanted GLP-1 medications for weight loss had to pay out of pocket — often more than $1,000 per month. That changes on July 1, 2026, when the Medicare GLP-1 Bridge program launches, capping copays at $50 per month for eligible beneficiaries.

This guide covers who qualifies, which medications are covered, and how to make sure your prescription is approved before the program goes live.

What Is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term pilot program created by the Centers for Medicare & Medicaid Services (CMS). It runs from July 1, 2026 through December 31, 2027, and is designed to bridge the gap before a longer-term coverage model — the BALANCE Model — potentially begins in 2028.

Under the Bridge, eligible Medicare Part D enrollees can access FDA-approved weight-loss GLP-1s at a flat copay of $50 per month, regardless of which benefit phase they're in. That's a reduction of 95% or more from list prices that can exceed $1,400 monthly.

Which Medications Are Covered?

Three medications are covered under the Bridge program specifically for weight management:

• Wegovy — both the pill and injectable formulations (semaglutide)
• Zepbound KwikPen — the injectable tirzepatide formulation
• Foundayo — the oral orforglipron pill (FDA-approved April 2026)

Who Qualifies?

You must be enrolled in a Medicare Part D plan (standalone PDP or Medicare Advantage with drug coverage). Beyond that, eligibility is clinical:

Phase 1 (July 2026):

• BMI ≥ 27 with cardiovascular disease, prediabetes, hypertension, or peripheral artery disease
• BMI ≥ 30 with heart failure (preserved ejection fraction), uncontrolled hypertension, or CKD stage 3a+
• BMI ≥ 35 — automatic qualification, no additional comorbidity required

Phase 2 (January 2027):

• BMI ≥ 30 without additional comorbidities — broadened access

Already on a GLP-1?

If you started a GLP-1 before the Bridge launched and have since lost weight, your provider attests to the BMI you had when treatment began — not your current BMI. For example, if you started in 2024 with a BMI of 37 and now weigh less, you still qualify based on your starting BMI.

How to Get Your Prescription Approved

The Bridge program requires prior authorization. Your prescriber will need to:

1. Submit documentation confirming you meet BMI thresholds
2. Attest to qualifying comorbidities (if BMI is below 35)
3. Specify the covered medication (Wegovy, Zepbound KwikPen, or Foundayo)

Claims are processed through a dedicated BIN/PCN established by CMS. You fill your prescription at any participating pharmacy — pharmacies don't need to opt in, they automatically participate.

What to Do Before July 1

If you're on Medicare and interested in starting (or continuing) a GLP-1 for weight loss, here's your checklist:

• Confirm your Part D plan is active
• Schedule a visit with your prescriber in June to discuss eligibility
• Gather documentation: most recent BMI, lab work showing comorbidities, weight history
• Ask your prescriber to prepare the prior authorization submission in advance
• Verify which of the three covered medications your doctor recommends

What If You Don't Qualify for the Bridge?

If your BMI or health conditions don't meet the Bridge criteria, you still have options. Several telehealth providers offer cash-pay GLP-1 programs at prices significantly below brand-name retail.

You can also check whether your Medicare Advantage plan offers any separate weight management benefits — some plans provide more comprehensive support than standard Part D.